Melanogenesis inhibition

Melanogenesis inhibition refers to the therapeutic reduction or blockade of melanin production in melanocytes, most often by targeting key enzymes such as tyrosinase or regulators like MITF (microphthalmia-associated transcription factor), as well as multiple related signaling pathways (e.g., cAMP, PKA, CREB, ERK). While critical for hyperpigmentation disorders, cancer, and melasma treatments, "melanogenesis inhibition" is not the name of a molecular target. Instead, specific targets in this process include enzymes (tyrosinase, TRP-1, TRP-2), transcription factors (MITF), and regulatory proteins and pathways (α-MSH, cAMP/PKA/CREB, ERK/AKT/GSK3β). Melanogenesis inhibitors may include small molecules such as kojic acid, arbutin, resveratrol derivatives, cinnamic acid derivatives, omeprazole, and ML233, all of which act by directly or indirectly inhibiting enzymes or signaling regulators in the melanogenesis pathway. The major direct therapeutic target for melanogenesis inhibition is tyrosinase (full name: Monophenol monooxygenase). The regulation of melanogenesis involves a network of targets, including MITF, upstream kinases, and receptor pathways. "Melanogenesis inhibition" should not be treated as a canonical molecular target but as a biological process involving well-defined protein targets, most notably tyrosinase and MITF. For structured target lists, these molecular targets should be identified individually rather than grouping them under "Melanogenesis inhibition."

Other names

Melanogenesis suppressionMelanin inhibitionAnti-melanogenic action